Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2017-05-03 Remuneration Information
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Grant of Options and RSUs and PDMR Dealings
Remuneration Information Classification · 1% confidence The document is an RNS announcement dated May 3, 2017, titled 'Grant of Options and RSUs and PDMR Dealings'. It details the issuance of stock options and Restricted Share Units (RSUs) to directors and senior management (PDMRs) and reports on their corresponding transactions. This content specifically relates to insider trading reports and executive compensation/share dealings, which falls under the category of Director's Dealing (DIRS) or potentially Remuneration Information (DEF 14A). However, the core focus is the notification of transactions by PDMRs in the company's shares, which is the primary characteristic of a Director's Dealing report. Since it is an RNS announcement reporting insider transactions, DIRS is the most specific fit, although RNS is the source. Given the explicit content detailing PDMR dealings, DIRS is chosen over the general RNS fallback.
2017-05-03 English
Admission and First Day of Dealings
Share Issue/Capital Change Classification · 1% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory announcement. The content describes the readmission of the company's shares to trading on AIM following a name change and a placing (fundraising). This announcement details capital structure changes (£1.5 million raised, new share count, market capitalization) and future plans. While it involves capital (CAP) and management commentary, the primary nature of this filing, identified by the RNS header and its function as a general market update regarding a significant corporate event (readmission/relisting), fits best under the general regulatory announcement category, RNS. It is not a full financial report (10-K, IR), an earnings release (ER), or a specific proxy/dividend notice. Given the structure and the explicit 'RNS Number', RNS is the most appropriate classification for this type of general regulatory news release.
2017-05-03 English
Closing of Global Offering and Total Voting Rights
Capital/Financing Update Classification · 1% confidence The document is an official announcement released via RNS (RNS Number : 9700D) on May 2, 2017. The title explicitly states: "Verona Pharma Announces Closing of Global Offering and Resulting Total Voting Rights." The content details the successful closing of a capital raise (Global Offering) involving the issuance of new ordinary shares and ADSs, resulting in a change to the total issued share capital. This clearly falls under the category of financing activities and capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). Although it is an RNS announcement, the core subject matter is a specific corporate action (financing) rather than a general regulatory update, making CAP more precise than RNS.
2017-05-02 English
Director/PDMR Shareholding
Director's Dealing Classification · 1% confidence The document is an RNS announcement (indicated by 'RNS Number : 7852D' and the closing tag 'This information is provided by RNS The company news service from the London Stock Exchange'). The content explicitly details 'Director Purchases' and 'Related Party Transactions' involving the purchase of shares/ADSs by Persons Discharging Managerial Responsibilities (PDMRs) and related parties. This type of insider transaction reporting, especially when filed via RNS, directly corresponds to the definition of Director's Dealing (DIRS). Although it is an RNS announcement, the specific content is highly indicative of DIRS, which takes precedence over the general RNS fallback.
2017-05-02 English
Director/PDMR Shareholding
Director's Dealing Classification · 1% confidence The document is an RNS announcement (indicated by 'RNS Number : 7827D' and the closing line 'This information is provided by RNS The company news service from the London Stock Exchange'). The content explicitly details 'Director Purchases' and 'Related Party Transactions' involving the purchase of shares/ADSs by Persons Discharging Managerial Responsibilities (PDMRs). This type of insider transaction reporting, especially when filed via RNS, directly corresponds to the disclosure of personal share transactions by company directors and executives, which matches the definition for Director's Dealing (DIRS). Although it is an RNS announcement, the specific content is highly indicative of DIRS, making DIRS the most precise classification over the general RNS fallback.
2017-04-28 English
Pricing of Offering and Approval to List on NASDAQ
Share Issue/Capital Change Classification · 1% confidence The document is an RNS announcement (RNS Number : 4835D) dated April 27, 2017, detailing the 'Pricing of Global Offering and Approval to List on the NASDAQ Global Market'. It discusses the pricing of new ordinary shares and ADSs, aggregate proceeds, underwriting details, and expected listing dates. This clearly relates to a corporate financing activity, specifically an equity offering and listing. This fits the definition of 'Capital/Financing Update' (CAP). Although it is distributed via RNS, the core subject matter is financing, making CAP the most specific and appropriate classification over the general RNS fallback.
2017-04-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.